An overview of the development of pharmacotherapeutics targeting SARS-CoV-2

被引：1

作者：

Lucaj, Tom ^{[1
]}

Hay, Ian ^{[1
]}

Samarbakhsh, Amirreza ^{[1
]}

Bedi, Mel ^{[1
]}

Iyer, Arun K. ^{[1
]}

Gavande, Navnath S. ^{[1
,2
]}

机构：

[1] Wayne State Univ, Eugene Applebaum Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Detroit, MI 48201 USA

[2] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Sch Med, Mol Therapeut Program, Detroit, MI 48201 USA

来源：

DRUG DISCOVERY TODAY | 2024年 / 29卷 / 09期

基金：

美国国家卫生研究院;

关键词：

SARS-CoV-2/COVID-19; Pharmacotherapeutics; Monoclonal antibodies; Antiviral and immunomodulatory agents; NANOTECHNOLOGY; EFFICACY; COVID-19;

D O I：

10.1016/j.drudis.2024.104126

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Coronavirus disease 2019 (COVID-19) was declared global pandemic in March 2020, which precipitated urgent public health responses. The causative agent, SARS-CoV-2, spreads primarily via respiratory droplets, necessitating precautions to mitigate transmission risks. Biopharmaceutical industries and academic institutions worldwide swiftly redirected their research endeavors towards developing therapeutic interventions, focusing on monoclonal antibodies, antiviral agents, and immunomodulatory therapies. The evolving body of evidence surrounding these treatments has prompted successive updates and revisions from the FDA, delineating the evolving landscape of COVID-19 therapeutics. This review comprehensively examines each treatment modality within the context of their developmental trajectories and regulatory approvals throughout the pandemic. Furthermore, it elucidates their mechanisms of action and presents clinical data underpinning their utility in combating the COVID-19 crisis.

引用

页数：13

共 91 条

[1] Tixagevimab and Cilgavimab (Evusheld) for Pre-Exposure Prophylaxis of COVID-19 [J].